LEXEO THERAPEUTICS INC (LXEO)

US52886X1072 - Common Stock

6.25  -0.03 (-0.48%)

Fundamental Rating

2

LXEO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. While LXEO seems to be doing ok healthwise, there are quite some concerns on its profitability. LXEO has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LXEO has reported negative net income.
In the past year LXEO has reported a negative cash flow from operations.

1.2 Ratios

LXEO has a Return On Assets (-47.49%) which is in line with its industry peers.
LXEO's Return On Equity of -58.48% is fine compared to the rest of the industry. LXEO outperforms 61.92% of its industry peers.
Industry RankSector Rank
ROA -47.49%
ROE -58.48%
ROIC N/A
ROA(3y)-48.51%
ROA(5y)N/A
ROE(3y)-59.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

LXEO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

LXEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LXEO has been increased compared to 1 year ago.
The debt/assets ratio for LXEO has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 2.22 indicates that LXEO is not a great score, but indicates only limited risk for bankruptcy at the moment.
LXEO's Altman-Z score of 2.22 is fine compared to the rest of the industry. LXEO outperforms 72.60% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that LXEO is not too dependend on debt financing.
LXEO's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. LXEO outperforms 43.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 2.22
ROIC/WACCN/A
WACC10.9%

2.3 Liquidity

LXEO has a Current Ratio of 7.21. This indicates that LXEO is financially healthy and has no problem in meeting its short term obligations.
LXEO has a Current ratio of 7.21. This is in the better half of the industry: LXEO outperforms 68.68% of its industry peers.
A Quick Ratio of 7.21 indicates that LXEO has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.21, LXEO is doing good in the industry, outperforming 68.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.21
Quick Ratio 7.21

More info and screens

0

3. Growth

3.1 Past

The earnings per share for LXEO have decreased strongly by -12.14% in the last year.
LXEO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-12.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, LXEO will show a small growth in Earnings Per Share. The EPS will grow by 5.47% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.84%
EPS Next 2Y12.07%
EPS Next 3Y7.08%
EPS Next 5Y5.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LXEO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LXEO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.07%
EPS Next 3Y7.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LXEO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXEO THERAPEUTICS INC

NASDAQ:LXEO (12/23/2024, 10:36:42 AM)

6.25

-0.03 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners91.47%
Inst Owner Change8.68%
Ins Owners0.42%
Ins Owner Change0.35%
Market Cap206.69M
Analysts86.15
Price Target22.73 (263.68%)
Short Float %6.99%
Short Ratio5.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-190.48%
Min EPS beat(2)-366.42%
Max EPS beat(2)-14.55%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.64%
PT rev (3m)-0.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-12.81%
EPS NY rev (3m)-13.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.82
P/tB 1.82
EV/EBITDA N/A
EPS(TTM)-2.69
EYN/A
EPS(NY)-3.18
Fwd EYN/A
FCF(TTM)-1.8
FCFYN/A
OCF(TTM)-1.8
OCFYN/A
SpS0
BVpS3.43
TBVpS3.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.49%
ROE -58.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.51%
ROA(5y)N/A
ROE(3y)-59.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.6%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.21
Quick Ratio 7.21
Altman-Z 2.22
F-Score4
WACC10.9%
ROIC/WACCN/A
Cap/Depr(3y)753.98%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y22.84%
EPS Next 2Y12.07%
EPS Next 3Y7.08%
EPS Next 5Y5.47%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-13.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.43%
EBIT Next 3Y-3.96%
EBIT Next 5YN/A
FCF growth 1Y-7.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.05%
OCF growth 3YN/A
OCF growth 5YN/A